5PSQ-078 Secukinumab for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis in clinical practice

BACKGROUND: Moderate to severe psoriasis is considered a multisystem disease that is associated with the risk of other comorbidities complex inflammatory disease. Psoriatic arthritis (PsA) is a form of chronic arthritis associated with psoriasis. Secukinumab is a monoclonal antibody that blocks the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Eur J Hosp Pharm
Huvudupphovsmän: Martín, E García, Romero-Jiménez, R, Ais-Larisgoitia, A, Escudero-Vilaplana, V, Collado-Borrell, R, Martínez-Ortega, PA, Ortega-Navarro, C, Revuelta-Herrero, J, Amor-García, MA, García-Moreno, FJ, Sanjurjo-Sáez, M
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Group 2018
Ämnen:
Section 5: Patient safety and quality assurance
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535462/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.432
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk